CG
SMMT icon

Cutler Group’s Summit Therapeutics SMMT Stock Holding History

Cutler Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,600
Closed -$4K – 4139
2023
Q1 		$4K Sell
1,600
-5,900
-79% -$16.1K ﹤0.01% 2864
2022
Q4 		$14K Buy
+7,500
New +$13.6K ﹤0.01% 2490

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Cutler Group's SMMT Position: Q1 2024 in Review

Cutler Group reduced its Summit Therapeutics (SMMT) stake by 42% in Q1 2024, selling an estimated $48.1K and leaving 16,500 shares worth $68K. The position accounts for 0.02% of the portfolio, ranked #563.

Cutler Group first reported a position in SMMT in Q2 2020 and has held it in 12 quarters since. The position peaked at $74K in Q4 2023. 105 funds tracked by Wall St. Rank hold SMMT as of Q1 2024.

  • Cutler Group held 16,500 shares of Summit Therapeutics worth $68K as of Q1 2024.
  • Cutler Group sold 12,100 Summit Therapeutics shares in Q1 2024, an estimated $48.1K.
  • Summit Therapeutics made up 0.02% of Cutler Group's portfolio in Q1 2024, its #563 holding.
  • Cutler Group first reported a position in Summit Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • Cutler Group's Summit Therapeutics position peaked at $74K in Q4 2023.
  • 105 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.